UK National Health Service undertakes probiotic colon study

By Shane Starling

- Last updated on GMT

UK National Health Service undertakes probiotic colon study
King’s College Hospital in London is investigating the potential of a proprietary probiotic blend to benefit those suffering from diverticular disease.

The NHS-backed study is investigating if the blend can reduce pain, bloating and diarrhoea or constipation that can occur with the ailment that causes pouches to form in the colon.

Research shows 25% of the UK population will develop diverticula by the time they reach 60; two-thirds by the age of 85. Of those about 20% develop diverticulitis, when the pouches become inflamed and infected by bacteria from trapped faeces.

The typical treatment in these cases are antibiotics, or surgery.

“Patients with diverticulitis frequently develop symptoms reminiscent of  irritable bowel syndrome after their attack,”​ said lead researcher, professor Ingvar Bjarnason.

“Intestinal bacteria undoubtedly play an important role in diverticulitis and it is hoped that by modifying the gut flora [the blend] will improve their symptoms.”

The double-blind placebo controlled trial is being run with 200 patients with symptoms of diverticulitis and uses a probiotic product manufactured by UK start-up going by the same name as the product – Symprove.

There are four probiotic strains in Symprove – L. casei, L. acidophilus, L. plantarum​ and E. faecium​. It contains 10 billion colony forming units – the standard measure of probiotic content – per 50ml serving.

Study set-up

Patients will receive 1ml/kg/day for three months with the placebo containing all the ingredients in Symprove except the probiotic strains.

Patients will visit the lab monthly and be offered post-trial treatment for two months for the control and five months for the placebo group.

Related news

Show more

Related products

show more

BB536 for optimal Gut health and beyond

BB536 for optimal Gut health and beyond

Content provided by Morinaga Milk Industry Co., Ltd. | 03-Oct-2024 | White Paper

Among the various probiotics strains available, Bifidobacterium longum BB536 stands out due to its well-documented safety, efficacy, and regulatory approvals....

Unlock sensory innovation with AromatiQ™ technology

Unlock sensory innovation with AromatiQ™ technology

Content provided by Lonza | 20-Sep-2024 | Product Brochure

With 70% of consumers willing to pay a premium for a more enjoyable and memorable supplement experience, Lonza’s new AromatiQ™ technology enables brands...

Related suppliers

Follow us

Products

View more

Webinars